French biotech lands manufacturing deal in step toward commercialization of rare bone disease drug
As a startup, it can sometimes be tough to think too far ahead in the future. However, with a major manufacturing partnership announced Wednesday, CTO Carole Schwintner and her team at MaaT Pharma are taking the first steps toward establishing a long-term game plan for the seven-year-old company.
The French biotech and CDMO Skyepharma will partner to build the largest specialized manufacturing facility for microbiome-based therapeutics. The plant will help MaaT increase its output by ten-fold by 2030, with the aim to produce several thousand enemas of the lead candidate MaaT-013, to treat Graft-versus-Host disease (GvHD), which happens when donated bone marrow or stem cells view the recipient’s body as foreign, and donated cells and bone marrow attack the body. It will also produce “several hundreds of thousands capsules” of MaaT-033, for patients who receive an allogeneic stem cell transplantation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
